NCT04250506

A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

A Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, Phase 1 Study to Assess the Effect of Single Therapeutic and Supratherapeutic Doses of Daridorexant on the QT Interval Duration in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Idorsia Pharmaceuticals Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A study to assess the effect of single doses of daridorexant on electrocardiogram parameters in healthy subjects

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Daridorexant	Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
DRUG	Placebo	Placebo administered as tablets for oral use.
DRUG	Moxifloxacin	Moxifloxacin administered as film-coated tablets for oral use.

Timeline

• Start date: 2020-02-28
• Primary completion: 2020-07-22
• Completion: 2020-07-22
• First posted: 2020-01-31
• Last updated: 2020-09-16

Locations

1 site across 1 country: Czechia